European Defense Stocks Slide on Push for Peace in Ukraine, Gaza
A Goldman Sachs Group Inc. basket of European defense stocks dropped as much as 5.7% after the news. In Germany, tank and ammunitions supplier Rheinmetall AG slid as much as 4.9% while gearbox maker Renk Group AG hit its lowest since May.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Former Nokia CEO joining Finnish quantum company's board
STOCKHOLM (Reuters) -Former Nokia CEO Pekka Lundmark will join Finnish quantum computing company QMill as an investor and a board member, the company said on Wednesday. Lundmark stepped down from the top job at Nokia earlier this year after being appointed as CEO in 2020, and is credited with turning around the telecom gear maker. Antti Vasara, former head of VTT Technical Research Centre of Finland, and a former Nokia executive, will also join QMill as chair of the board. Espoo, Finland-based QMill, is a quantum-algorithm company, which started operations last year, and has raised seed funding from Antler, and Kvanted. Quantum computing is emerging as a promising sector where many startups are working alongside tech companies such as Microsoft and Nvidia to build functional computers to solve problems that would take classical computers thousands of years. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
25 minutes ago
- Yahoo
Airbus workers to stage strikes amid pay dispute
Workers at aircraft manufacturer Airbus are to stage a series of strikes in a dispute over pay. Unite said around 3,000 of its members will walk out for 10 days in September after they voted overwhelmingly in favour of industrial action. Unite general secretary Sharon Graham said: 'Airbus is generating billions in profit; workers deserve a fair deal. Our members are simply seeking fairness not favours. 'Airbus workers have the total support of their union in this dispute.' Unite warned the strikes will hit production of wings for Airbus's commercial and military aircraft programmes.
Yahoo
25 minutes ago
- Yahoo
Coloplast AS (CLPBF) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amidst Challenges
This article first appeared on GuruFocus. Organic Revenue Growth: 7% for the third quarter. EBIT Margin Before Special Items: 28% in the third quarter. Adjusted Return on Invested Capital: 15%, on par with last year. Ostomy Care Organic Growth: 6% for the first nine months. Continence Care Organic Growth: 8% for the first nine months. Voice and Respiratory Care Organic Growth: 9% for the first nine months. Advanced Wound Care Organic Growth: 9% for the first nine months. Kerecis Growth: 26% for the first nine months. Interventional Urology Organic Growth: 1% for the first nine months. Gross Margin: 68% for the first nine months. Operating Profit Before Special Items: DKK 5.7 billion for the first nine months. Net Profit Before Special Items: DKK 3.8 billion for the first nine months. Operating Cash Flow: DKK 4.4 billion for the first nine months. Free Cash Flow: DKK 3.5 billion for the first nine months. CapEx: 5% of sales for the first nine months. Warning! GuruFocus has detected 4 Warning Signs with CLPBF. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Coloplast AS (CLPBF) reported a 7% organic growth for the third quarter, driven by broad-based growth across its Chronic Care businesses. The company has reorganized its structure into two business units, Chronic Care and Acute Care, to better address market dynamics and customer needs. Coloplast AS (CLPBF) is focusing on innovation, with plans to bring new products to market faster and enhance R&D capabilities. The company has maintained a stable EBIT margin of 27% to 28% before special items, demonstrating effective cost management. Kerecis, a part of the Advanced Wound Care segment, showed strong growth of 26% in the first nine months, indicating robust demand for its products. Negative Points The Advanced Wound Care business fell short of expectations due to product returns in China and lower-than-expected growth for Kerecis. The US Centers for Medicare and Medicaid Services proposed rules that could impact Coloplast AS (CLPBF)'s Chronic Care business, introducing uncertainty about future financial impacts. The company faced a negative impact from foreign exchange rates, which reduced reported revenue by approximately 1%. Coloplast AS (CLPBF) experienced a product recall in China, leading to a significant negative financial impact in the third quarter. The Bladder Health and Surgery segment continued to detract from growth, with uncertainty around the timeline for full recovery. Q & A Highlights Q: Lars, we've seen product recalls and execution issues. What steps are you taking to prevent future recalls? A: Lars Rasmussen, Interim CEO: The recall of urological products was due to a sterilization barrier breach, a common issue in the industry. The situation in China with Biatain foam products is different; it's a technical specification issue unique to China, not a quality problem. We're discussing this with the market and working on substitute products, but it's a slow process. Q: Can you elaborate on the INTIBIA filing and your confidence in regulatory acceptance? A: Anders Lonning-Skovgaard, CFO: We are on track with the INTIBIA launch and expect to get it through the FDA process in the US. We anticipate launching in the first part of the next strategic period. Q: Regarding Kerecis, how was growth in non-physician office settings, and what are the incentives for physicians to use higher-priced products? A: Anders Lonning-Skovgaard, CFO: In Q3, high-priced products reentered the market due to an LCD delay, impacting sales. We expect a bounce back in Q4. The new skin substitute price is being discussed and expected to be implemented in January 2026. Q: On the competitive bidding proposal, can you provide more details on the potential impact on US Chronic Care sales? A: Lars Rasmussen, Interim CEO: It's difficult to estimate the impact, but competitive bidding on specialized products like Ostomy Care seems illogical due to the complexity and variety of SKUs. We estimate around 50% of our US sales are Medicare-related. Q: Can you explain the rationale behind establishing R&D franchises within Chronic Care? A: Lars Rasmussen, Interim CEO: Innovation is crucial, and we aim to bring products to market faster and derive more value from them. This change elevates R&D to the executive level to ensure close collaboration with manufacturing, enhancing both innovation and profitability. For the complete transcript of the earnings call, please refer to the full earnings call transcript.
